Pex Machina: Part two deep dive interview: CEO Matthias Kaiser

The future of quantum is already touching patientsIn Part 2 of my deep-dive with MatthiasKaiser, CEO of Pex Machina, we explore how quantum simulationis changing drug discovery and why the next medical breakthroughs might comefrom software, not the lab.Pex Machina’smission is simple: help companies develop better cancer treatments.Quantum simulation is the tool that makes it possible, cutting the time, cost, and risk of new drug development.What impressed memost is how Matthias thinks about execution.He built a team that combines deep domain knowledge from pharma with real quantum expertise.They move fast, learn from every iteration, and build proof instead of PowerPoints.Matthias said something that stayed with me:“We’re not building technology for technology’s sake. We’re building tools that solve real problems.”What stood out in this part of our conversation:💡 Why precision medicine needs better simulationtools to scale🧠 How pharma collaboration is about access andtrust, not just algorithms🚀 Why execution speed and real-world validationmatter more than hype🎧 Listento Beyondthe Qubit – Pex Machina (Deep Dive Part 2)👉 [Insert Spotify or YouTube link]https://youtu.be/KN3LWO07Ol8  #BeyondTheQubit#QuantumComputing #PrecisionMedicine #DeepTech #Innovation #PexMachina #AI#DrugDiscovery Please do not forget to check out the presentationfrom Matthias (CEO of Pex Machina)https://drive.google.com/file/d/18LwU4QNtl3nRDAIcPWQ9kb2VLintVQEY/view?usp=drive_link 📌 Disclaimer: This post is shared on a personal basis and I do notrepresent any company

There are no comments yet.

Please log in to write the first comment.